Announced details
Intranasal mucosal vaccines; prevention of influenza virus infection
The system induced secretory IgA production in nasal lavage fluid and was confirmed in cynomolgus monkeys to prevent influenza virus infection from taking hold in the nasal mucosa. Numerical data are Not disclosed
The company conducts R&D under a commissioned research contract with AMED
A National Research and Development Agency with the Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA); other details, including location, representative, capital and year established, are Not disclosed
Intranasal Mucosal Vaccine R&D Center (location Not disclosed)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
AMED's website, "Interim Evaluation of the FY2025 Vaccine and Novel Modality Research and Development Program" and "Interim Evaluation Results Report"
| Item | Details |
|---|---|
| Names of Products / Services Covered | Powder-jet intranasal vaccine system for inducing IgA production |
| Counterparty | Japan Agency for Medical Research and Development (AMED) |
| Counterparty overview | A National Research and Development Agency with the Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA); other details, including location, representative, capital and year established, are Not disclosed |
| Relationship with the Company | The company conducts R&D under a commissioned research contract with AMED |
| Contract Date | March 2024 (when the commissioned research contract with AMED was obtained) |
| Applicable area | Intranasal mucosal vaccines; prevention of influenza virus infection |
| Location | Intranasal Mucosal Vaccine R&D Center (location Not disclosed) |
| Quantitative Effects | The system induced secretory IgA production in nasal lavage fluid and was confirmed in cynomolgus monkeys to prevent influenza virus infection from taking hold in the nasal mucosa. Numerical data are Not disclosed |
| Source | AMED's website, "Interim Evaluation of the FY2025 Vaccine and Novel Modality Research and Development Program" and "Interim Evaluation Results Report" |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The project achieved nonclinical proof of concept and demonstrated in cynomolgus monkeys that it could prevent influenza virus infection from taking hold in the nasal mucosa.